Article
Suppression of pancreatic tumor progression by systemic delivery of a pancreatic-cancer-specific promoter driven Bik mutant.
Cancer letters - 8 May 2006
Li Zheng, Ding Qingqing, Li Yan, Miller Stephanie A, Abbruzzese James L, Hung Mien-Chie
Abstract excerpt
Pancreatic cancer is highly aggressive with extremely poor prognosis. Developing a pancreatic cancer specific promoter (PCSP) is one approach for pancreatic cancer gene therapy. We have modified the promoter of cholecystokinin type A receptor (CCKAR), named CCK/Mpd, which possesses a relatively high activity in pancreatic cancer cells as compared with normal cells. The CCK/Mpd promoter-driven luciferase exhibits...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
